A Phase 4 interventional study of Ranibizumab 0.5 mg and Aflibercept 2.0 mg in Age-Related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 22 sites in Australia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-06-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Geographic Atrophy by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Geographic Atrophy · Novartis.
Among the 15 studies in Geographic Atrophy by Novartis, this one is the 4th largest by enrollment, is one of 2 that started in 2014, is one of 6 in phase 4, and was the 4th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →1 of the 15 studies in Geographic Atrophy by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 16 more countries
Ages 50+
By country, each count listing its studies:
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 281 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 158 across the 15 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Geographic Atrophy by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare the development of new geographic atrophy in patients with wet Age-related Macular Degeneration (AMD) when treated with either ranibizumab or aflibercept over 24 months. Geographic atrophy is an advanced form of AMD that can result in the progressive and irreversible loss of visual function over time.
In each arm, patients underwent three monthly loading doses (at Baseline, Week 4, and Week 8). From Week 8, after the patient had received their third injection of study treatment, the visit intervals were determined by the patient's disease activity. If any of the protocol-specified signs of disease activity were present in the study eye, the subsequent injection visit interval was kept at 4 weeks. If none of the signs were present, the subsequent injection interval was extended by 2-week increments up until a maximum of 12-weekly intervals was reached. If there were any signs of disease activity in the study eye, the treatment interval was reduced as specified in the protocol. The planned individual duration of study participation was 24 months.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
This study's enrollment of 281 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Browse Geographic Atrophy studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Geographic Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion criteria:
Inclusion criteria specific to the study eye:
Exclusion criteria:
Exclusion criteria specific to the study eye:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity \[treat and extend\]
Drug: Ranibizumab 0.5 mg
3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity \[treat and extend\]
Drug: Aflibercept 2.0 mg
Administered as an intravitreal injection
Also known as: Lucentis
Administered as an intravitreal injection
Also known as: Eylea
Mean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24
Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center, where the area of GA was measured. Area was treated as zero if GA was reported as absent (Overall determination of GA presence). Mean change from baseline in GA area was reported in square root-transformed data (mm). One eye (study eye) contributed to the analysis.
Time frame: Baseline, Month 24
Mean Change in Square-root Area of Geographic Atrophy From Baseline to Month 12
Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center, where the area of GA was measured. Area was treated as zero if GA was reported as absent (Overall determination of GA presence). Mean change from baseline in GA area was reported in square root-transformed data (mm). One eye (study eye) contributed to the analysis.
Time frame: Baseline, Month 12
Percentage of Patients With Newly Developed Geographic Atrophy During the Overall 24 Months of the Study
Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center. A patient was considered to have developed new GA if they did not have any GA at the start of the study period and were subsequently diagnosed with GA during the study period (diagnosis of GA change from "No" to "Yes)." The analysis of new GA development was restricted to only those subjects without GA reported at baseline. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Month 12, Month 24
Mean Number of Intravitreal Injections From Baseline to Month 12 and to Month 24
The number of intravitreal injections was calculated. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Month 12, Month 24
Mean Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12 and to Month 24
Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. BCVA change was defined as a change in letters correctly identified from the baseline assessment. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis
Time frame: Baseline, Month 12, Month 24
Mean Change in Central Subfield Foveal Thickness (CSFT) From Baseline to Month 12 and to Month 24
CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Optical Coherence Tomography (OCT) and measured in micrometers. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis
Time frame: Baseline, Month 12, Month 24
Percentage of Patients Showing no Intraretinal Fluid (IRF)/Subretinal Fluid (SRF)
Intraretinal fluid and subretinal fluid was assessed using Optical Coherence Tomography (OCT) and recorded as Present/Absent. One eye (study eye) contributed to the analysis.
Time frame: Month 2, Month 12, Month 24
Percentage of Patients Showing Greater Than and Equal to 15 Letters Gain for BCVA From Baseline to Month 12 and to Month 24
Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. A gain in letters correctly identified indicates an improvement in visual acuity, while a loss indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Month 12, Month 24
Percentage of Patients Showing Less Than and Equal to 15 Letters Loss for BCVA From Baseline to Month 12 and to Month 24
Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. A gain in letters correctly identified indicates an improvement in visual acuity, while a loss indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Month 12, Month 24
Mean Number of Times a Patient Needed to Return to Monthly Intravitreal Injections Over 24 Months
The number of times the patient returned to a monthly injection interval (from an extended interval) at least once during the 24-month study was calculated. One eye (study eye) contributed to the analysis.
Time frame: Month 24
Mean Change in Vascular Endothelial Growth Factor (VEGF) Plasma Concentration From Baseline to 7 Days After the Second and 7 Days After the Third Mandated Intravitreal Injection of Treatment
Blood for VEGF plasma concentration analysis was collected at Baseline and again at 7 days after the injection at Week 4 and 7 days after the injection at Week 8.
Time frame: Baseline, Week 5, Week 9
Percentage of Patients With Change in Retinal Nerve Fibre Thickness From Baseline to Month 12 and Month 24
Retinal nerve fibre thickness was assessed using Optical Coherence Tomography (OCT) and measured in micrometers. A negative change in value (i.e. thinner nerve fibre) indicates nerve damage. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Month 12, Month 24
Percentage of Patients With Ocular Inflammation at Baseline and 7 Days Post-injection Following 3rd Mandated Intravitreal Injection - Anterior Chamber Cells
Anterior cell grade was assessed by the Investigator during slit lamp examination and graded on a 5-point scale: Grade 0=0 cells; Grade 1=1 to 10 cells; Grade 2=11 to 20 cells; Grade 3=21 to 50 cells; Grade 4=\>50 cells. The presence of blood cells (red and white) in the anterior chamber of the eye (the fluid-filled space inside the eye between the iris and the cornea's innermost surface) is a sign of intraocular inflammation. A score of 0 indicates an absence of inflammation. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Week 9
Percentage of Patients With Ocular Inflammation at Baseline and 7 Days Post-injection Following 3rd Mandated Intravitreal Injection - Anterior Chamber Flare
Anterior chamber flare was assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = none; 1 = mild (trace to clearly noticeable, visible); 2 = moderate; 3 = marked; and 4 = severe. The presence of flare (increased protein levels) in the anterior chamber of the eye (the fluid-filled space inside the eye between the iris and the cornea's innermost surface) is a sign of intraocular inflammation. A score of 0 indicates an absence of inflammation. Proportion of patients is reported as a percentage. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Week 9
Patients were recruited and enrolled from 24 sites located in Australia.
| Milestone | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Started | 142 | 139 |
| Safety set | 141 | 139 |
| Full analysis set (fas) | 141 | 137 |
| Completed | 117 | 108 |
| Not completed | 25 | 31 |
| Withdrew: Adverse event | 10 | 11 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 1 | 3 |
| Withdrew: Protocol deviation | 4 | 0 |
| Withdrew: Site administration problems | 1 | 0 |
| Withdrew: Subject withdrew consent | 6 | 14 |
Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center, where the area of GA was measured. Area was treated as zero if GA was reported as absent (Overall determination of GA presence). Mean change from baseline in GA area was reported in square root-transformed data (mm). One eye (study eye) contributed to the analysis.
| mm | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Baseline | 0.024 ± 0.0988 | 0.050 ± 0.2345 |
| Change from Baseline at Month 24 | 0.363 ± 0.7105 | 0.285 ± 0.5392 |
Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center, where the area of GA was measured. Area was treated as zero if GA was reported as absent (Overall determination of GA presence). Mean change from baseline in GA area was reported in square root-transformed data (mm). One eye (study eye) contributed to the analysis.
| mm | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Baseline | 0.024 ± 0.0988 | 0.050 ± 0.2345 |
| Change from Baseline at Month 12 | 0.155 ± 0.4272 | 0.145 ± 0.3179 |
Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center. A patient was considered to have developed new GA if they did not have any GA at the start of the study period and were subsequently diagnosed with GA during the study period (diagnosis of GA change from "No" to "Yes)." The analysis of new GA development was restricted to only those subjects without GA reported at baseline. One eye (study eye) contributed to the analysis.
| percentage of patients | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Baseline to Month 12 | 17.6 | 20.3 |
| Month 12 to Month 24 | 15.1 | 7.2 |
| Baseline to Month 24 | 28.8 | 25.4 |
The number of intravitreal injections was calculated. One eye (study eye) contributed to the analysis.
| injections | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Baseline to Month 12 | 9.7 ± 2.78 | 9.7 ± 2.54 |
| Month 12 to Month 24 | 8.9 ± 3.24 | 8.3 ± 3.56 |
| Baseline to Month 24 | 17.7 ± 6.44 | 17.0 ± 6.3 |
Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. BCVA change was defined as a change in letters correctly identified from the baseline assessment. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis
| letters | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Baseline | 65.3 ± 15.10 | 65.1 ± 12.53 |
| Change from Baseline at Month 12 | 6.9 ± 12.25 | 5.2 ± 12.83 |
| Change from Baseline at Month 24 | 6.5 ± 14.38 | 5.3 ± 13.33 |
CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Optical Coherence Tomography (OCT) and measured in micrometers. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis
| micrometers | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Baseline | 468.2 ± 150.82 | 483.5 ± 168.05 |
| Change from Baseline at Month 12 | -147.2 ± 128.38 | -171.6 ± 150.12 |
| Change from Baseline at Month 24 | -151.3 ± 133.37 | -181.7 ± 155.48 |
Intraretinal fluid and subretinal fluid was assessed using Optical Coherence Tomography (OCT) and recorded as Present/Absent. One eye (study eye) contributed to the analysis.
| percentage of patients | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Month 2 | 56.9 | 61.3 |
| Month 12 | 55.9 | 63.6 |
| Month 24 | 57.3 | 60.6 |
Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. A gain in letters correctly identified indicates an improvement in visual acuity, while a loss indicates a worsening. One eye (study eye) contributed to the analysis.
| percentage of patients | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Change from Baseline at Month 12 | 22.0 | 20.7 |
| Change from Baseline at Month 24 | 24.8 | 18.5 |
Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. A gain in letters correctly identified indicates an improvement in visual acuity, while a loss indicates a worsening. One eye (study eye) contributed to the analysis.
| percentage of patients | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Change from Baseline at Month 12 | 96.9 | 95.0 |
| Change from Baseline at Month 24 | 94.0 | 94.4 |
The number of times the patient returned to a monthly injection interval (from an extended interval) at least once during the 24-month study was calculated. One eye (study eye) contributed to the analysis.
| occurrences | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Mean Number of Times a Patient Needed to Return to Monthly Intravitreal Injections Over 24 Months | 2.3 ± 1.28 | 2.3 ± 1.15 |
Blood for VEGF plasma concentration analysis was collected at Baseline and again at 7 days after the injection at Week 4 and 7 days after the injection at Week 8.
| picogram/milliliter (pg/mL) | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Baseline | 44.29 ± 43.369 | 41.88 ± 35.236 |
| Change from Baseline at Week 5 | -0.48 ± 30.299 | -26.37 ± 36.220 |
| Change from Baseline at Week 9 | 0.48 ± 35.125 | -25.14 ± 32.525 |
Retinal nerve fibre thickness was assessed using Optical Coherence Tomography (OCT) and measured in micrometers. A negative change in value (i.e. thinner nerve fibre) indicates nerve damage. One eye (study eye) contributed to the analysis.
| percentage of patients | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Month 12: Decrease from Baseline | 2.5 | 2.7 |
| Month 12: No Change from Baseline | 96.7 | 97.3 |
| Month 12: Increase from Baseline | 0.8 | 0 |
| Month 24: Decrease from Baseline | 3.6 | 1.0 |
| Month 24: No Change from Baseline | 96.4 | 97.9 |
| Month 24: Increase from Baseline | 0 | 1.0 |
Anterior cell grade was assessed by the Investigator during slit lamp examination and graded on a 5-point scale: Grade 0=0 cells; Grade 1=1 to 10 cells; Grade 2=11 to 20 cells; Grade 3=21 to 50 cells; Grade 4=\>50 cells. The presence of blood cells (red and white) in the anterior chamber of the eye (the fluid-filled space inside the eye between the iris and the cornea's innermost surface) is a sign of intraocular inflammation. A score of 0 indicates an absence of inflammation. One eye (study eye) contributed to the analysis.
| percentage of patients | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Baseline: Grade 0 | 99.3 | 98.5 |
| Baseline: Grade 1+ | 0.7 | 1.5 |
| Baseline: Grade 2+ | 0 | 0 |
| Baseline: Grade 3+ | 0 | 0 |
| Baseline: Grade 4+ | 0 | 0 |
| Week 9: Grade 0 | 95.1 | 92.7 |
| Week 9: Grade 1+ | 4.9 | 7.3 |
| Week 9: Grade 2+ | 0 | 0 |
| Week 9: Grade 3+ | 0 | 0 |
| Week 9: Grade 4+ | 0 | 0 |
Anterior chamber flare was assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = none; 1 = mild (trace to clearly noticeable, visible); 2 = moderate; 3 = marked; and 4 = severe. The presence of flare (increased protein levels) in the anterior chamber of the eye (the fluid-filled space inside the eye between the iris and the cornea's innermost surface) is a sign of intraocular inflammation. A score of 0 indicates an absence of inflammation. Proportion of patients is reported as a percentage. One eye (study eye) contributed to the analysis.
| percentage of patients | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Baseline: Grade 0 | 97.8 | 99.3 |
| Baseline: Grade 1+ | 2.2 | 0.7 |
| Baseline: Grade 2+ | 0 | 0 |
| Baseline: Grade 3+ | 0 | 0 |
| Baseline: Grade 4+ | 0 | 0 |
| Week 9: Grade 0 | 94.3 | 92.7 |
| Week 9: Grade 1+ | 5.7 | 7.3 |
| Week 9: Grade 2+ | 0 | 0 |
| Week 9: Grade 3+ | 0 | 0 |
| Week 9: Grade 4+ | 0 | 0 |
Collected over Adverse events were collected for the duration of the individual's participation in the study (approximately 24 months).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5 mg | 3/141 (2.1%) | 50/141 (35.5%) | 122/141 (86.5%) |
| Aflibercept 2.0 mg | 6/139 (4.3%) | 58/139 (41.7%) | 123/139 (88.5%) |
| Event | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Atrial fibrillation (Non-ocular)Cardiac disorders | 7/141 | 0/139 |
| Basal cell carcinoma (Non-ocular)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/141 | 2/139 |
| Pneumonia (Non-ocular)Infections and infestations | 4/141 | 4/139 |
| Urinary tract infection (Non-ocular)Infections and infestations | 2/141 | 4/139 |
| Squamous cell carcinoma (Non-ocular)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/141 | 4/139 |
| Cerebrovascular accident (Non-ocular)Nervous system disorders | 1/141 | 3/139 |
| Chest pain (Non-ocular)General disorders | 3/141 | 2/139 |
| Fall (Non-ocular)Injury, poisoning and procedural complications | 3/141 | 1/139 |
| Femoral neck fracture (Non-ocular)Injury, poisoning and procedural complications | 3/141 | 2/139 |
| Aphasia (Non-ocular)Nervous system disorders | 3/141 | 0/139 |
| Event | Ranibizumab 0.5 mg | Aflibercept 2.0 mg |
|---|---|---|
| Chest X-ray (Non-ocular)Investigations | 14/141 | 20/139 |
| Computerised tomogram (Non-ocular)Investigations | 6/141 | 18/139 |
| Eye pain (Left eye)Eye disorders | 10/141 | 15/139 |
| Urinary tract infection (Non-ocular)Infections and infestations | 11/141 | 15/139 |
| Fall (Non-ocular)Injury, poisoning and procedural complications | 11/141 | 15/139 |
| Nasopharyngitis (Non-ocular)Infections and infestations | 15/141 | 8/139 |
| Age-related macular degeneration (Right eye)Eye disorders | 10/141 | 14/139 |
| Cataract (Left eye)Eye disorders | 3/141 | 14/139 |
| Eye pain (Right eye)Eye disorders | 14/141 | 13/139 |
| Constipation (Non-ocular)Gastrointestinal disorders | 6/141 | 13/139 |
All patients randomized to treatment
| Age, Continuous(years) | Ranibizumab 0.5 mg | Aflibercept 2.0 mg | Total |
|---|---|---|---|
| Mean | 76.6 ± 8.5 | 78.7 ± 7.45 | 77.7 ± 8.06 |
| Sex: Female, Male(Participants) | Ranibizumab 0.5 mg | Aflibercept 2.0 mg | Total |
|---|---|---|---|
| Female | 72 | 76 | 148 |
| Male | 70 | 63 | 133 |
| Race/Ethnicity, Customized(participants) | Ranibizumab 0.5 mg | Aflibercept 2.0 mg | Total |
|---|---|---|---|
| Caucasian | 132 | 130 | 262 |
| Black African | 0 | 1 | 1 |
| Asian | 8 | 7 | 15 |
| Other | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2014 to primary completion in Nov 2017, 43 months.
Results were first posted in Jun 2019, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab